# Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC

Source: https://onco.cc/trials/nct03463252/  
OnCo record `nct03463252` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Progestins in Endometrial cancer, run by West China Second University Hospital, now recruiting.

## Summary

Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC is a phase 2/3 interventional study registered as NCT03463252 by West China Second University Hospital, with 224 participants planned, started 2018-04-01 and due to reach its primary completion in 2025-12-30. Interventions recorded: Progesterone, Mirena®, GnRH agonist. Conditions recorded: Endometrial Cancer, Atypical Endometrial Hyperplasia.

Linked to the drug Progestins because the registry names it among its interventions and Endometrial cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03463252
- Phase: 2/3
- Setting: Value of Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Fertility-preserving Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Carcinoma
- Sponsor: West China Second University Hospital
- Enrolled: 224

## Sources

- ClinicalTrials.gov NCT03463252: https://clinicaltrials.gov/study/NCT03463252

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- drugs: [Progestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD)](https://onco.cc/drugs/megestrol-progestins/)

---
JSON: https://onco.cc/api/v1/entities/nct03463252.json